Previous 10 | Next 10 |
2023-03-23 10:06:23 ET Gainers: ZyVersa Therapeutics ( ZVSA ) +33% . Aziyo Biologics ( AZYO ) +29% . Generation Bio ( GBIO ) +20% . HTG Molecular Diagnostics ( HTGM ) +16% . scPharmaceuticals ( SCPH ) +15% . Losers:...
2023-03-23 08:27:39 ET Society Pass ( SOPA ) -22% on Q4 earnings release . JanOne ( JAN ) -15% on $422K stock offering . Coinbase Global ( COIN ) -12% as SEC warns of potential charges ; downgraded to Perform at Oppenheimer after Wells n...
2023-03-23 07:53:26 ET Cidara Therapeutics press release ( NASDAQ: CDTX ): Q4 GAAP EPS of -$0.19 misses by $0.04 . Revenue of $10.22M (+41.9% Y/Y) misses by $0.35M . Cash and cash equivalents totaled $32.7 million as of December 31, 2022, co...
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the three months and full ye...
2023-03-23 04:49:08 ET The U.S. Food and Drug Administration (FDA) approved Cidara Therapeutics ( NASDAQ: CDTX ) and Melinta Therapeutics' Rezzayo (rezafungin for injection) to treat candidemia and invasive candidiasis in adults with limited or no alternative treatment...
– REZZAYO is a novel, once-weekly, next-generation echinocandin indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options – – REZZAYO is the first new FDA-approved echinocandin in over a decade ȁ...
– REZZAYO is a novel, once-weekly, next-generation echinocandin indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options – – REZZAYO is the first new FDA-approved echinocandin in over a decade ...
2023-03-22 08:21:40 ET 89bio ( ETNB ) +50% on topline data for NASH candidate. GameStop ( GME ) +48% on Q4 earnings. Telesis Bio ( TBIO ) +17% on Q4 earnings. Pyxis Oncology ( PYXS ) +11% on Q4 earnings. Ollie's Bargain O...
2023-03-22 08:17:48 ET After reaching a 52-week high in the previous session, Cidara Therapeutics ( NASDAQ: CDTX ) continued to trade higher in the pre-market Wednesday as the biotech awaits the FDA decision on its antifungal therapy rezafungin. In September, the FDA accep...
2023-03-18 10:30:11 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports a...
News, Short Squeeze, Breakout and More Instantly...
Cidara Therapeutics Inc. Company Name:
CDTX Stock Symbol:
NASDAQ Market:
Cidara Therapeutics Inc. Website:
2024-07-16 23:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious...
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients ...